CURVE THERAPEUTICS LIMITED

11989962
Active Southampton

Other professional, scientific and technical activities n.e.c.

23 employees website.com
Life sciences and medical technology Other professional, scientific and technical activities n.e.c.
C

CURVE THERAPEUTICS LIMITED

11989962

Other professional, scientific and technical activities n.e.c.

Founded 10 May 2019 Active Southampton, United Kingdom 23 employees website.com
Life sciences and medical technology Other professional, scientific and technical activities n.e.c.
Accounts Submitted 15 May 2025 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 8 Jun 2026 Next due 23 May 2027 11 months remaining
Net assets £16M £17M 2024 year on year
Total assets £26M £22M 2024 year on year
Total Liabilities £10M £5M 2024 year on year
Charges 1
1 satisfied

Contact & Details

Contact

Registered Address

Delta House Enterprise Road Southampton Science Park Southampton SO16 7NS United Kingdom

Website

www.example.com

Full company profile for CURVE THERAPEUTICS LIMITED (11989962), an active life sciences and medical technology company based in Southampton, United Kingdom. Incorporated 10 May 2019. Other professional, scientific and technical activities n.e.c.. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type small
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Balance Sheet & P&L (2020–2024)

Cash in Bank

£886.74k

Decreased by £795.53k (-47%)

Net Assets

£15.62M

Increased by £16.63M (+1645%)

Total Liabilities

£10.27M

Increased by £5.37M (+109%)

Turnover

N/A

Employees

23

Increased by 6 (+35%)

Debt Ratio

40%

Decreased by 86 (-68%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 2

Investors (5)

Investor NameInvestor SinceParticipating Rounds
Investor 1Jun 2019Seed, Series A
Investor 2Jun 2019Seed, Series A
Investor 3Feb 2024Series A

Share Capital

Share Capital

Share allotments and capital structure

3 Allotments 28,159,547 Shares £27.78m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
19 May 20261,137,485£5k£0.005
29 Jan 202425,022,062£25.77m£1.03
13 May 20212,000,000£2.00m£1

Officers

Officers

3 active
Status
Armstrong, RobertDirectorAmericanUnited States6912 Jan 2024Active
Hoekema, Andreas, DrDirectorDutchNetherlands681 Sept 2024Active
Malik, ShahzadDirectorBritishEngland5927 Jun 2019Active

Shareholders

Shareholders (24)

Columbus Life Science Fund Iv, F.c.r
19.4%
6,178,287
Pfizer Ventures (us) Llc
19.4%
6,178,287

Persons with Significant Control

Persons with Significant Control (0)

0 Active 3 Ceased

Advent Life Sciences Llp

Ceased 29 Jan 2024

Ceased

Professor Ali Tavassoli

Ceased 31 Jul 2020

Ceased

Epidarex Capital Iii Uk Lp

Ceased 29 Jan 2024

Ceased

Group Structure

Group Structure

No group structure identified

Charges

Charges

1 satisfied

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
8 Jun 2026OfficersChange to director Mr Robert Armstrong on 8 Jun 2026
8 Jun 2026OfficersChange to director Mr Shahzad Malik on 8 Jun 2026
8 Jun 2026Confirmation StatementConfirmation statement made on 9 May 2026 with updates
8 Jun 2026OfficersChange to director Ms Marie-Claire Peakman on 8 Jun 2026
5 Jun 2026CapitalAllotment of shares (GBP 3,305.9547) on 21 May 2026
8 Jun 2026 Officers

Change to director Mr Robert Armstrong on 8 Jun 2026

8 Jun 2026 Officers

Change to director Mr Shahzad Malik on 8 Jun 2026

8 Jun 2026 Confirmation Statement

Confirmation statement made on 9 May 2026 with updates

8 Jun 2026 Officers

Change to director Ms Marie-Claire Peakman on 8 Jun 2026

5 Jun 2026 Capital

Allotment of shares (GBP 3,305.9547) on 21 May 2026

Recent Activity

Latest Activity

Change to director Mr Robert Armstrong on 8 Jun 2026

1 weeks ago on 8 Jun 2026

Change to director Mr Shahzad Malik on 8 Jun 2026

1 weeks ago on 8 Jun 2026

Confirmation statement made on 9 May 2026 with updates

1 weeks ago on 8 Jun 2026

Change to director Ms Marie-Claire Peakman on 8 Jun 2026

1 weeks ago on 8 Jun 2026

Allotment of shares (GBP 3,305.9547) on 21 May 2026

2 weeks ago on 5 Jun 2026